{"denoms":[{"counts":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"13"}],"units":"Participants"}],"groups":[{"description":"Subjects with hematological malignancies with prior autologous transplant, \\>2 cycles of multiagent chemotherapy, or severely immune suppressive therapy in last 3 months, OR patients with refractory leukemia and lymphoma in aplasia after induction chemotherapy or radioimmunoconjugated monoclonal antibody therapy.\n\n* Cyclophosphamide 50 mg/Kg Day -6\n* Fludarabine 40mg/m2 Days -6 to -2\n* TBI 200 cGy Day -1\n\nImmune suppression begin Day -3: cyclosporine and mycophenolate mofetil","id":"BG000","title":"Cyclophosphamide/Fludarabine/TBI"},{"description":"Subjects with hematological malignancies with prior autologous transplant \\>12 mos or \\<1 cycle of multiagent chemotherapy or NO immune suppressive chemotherapy in last 3 months, and who should receive ATG as part of their conditioning regimen.\n\n* Cyclophosphamide 50 mg/Kg Day -6\n* Fludarabine 40mg/m2 Days -6 to -2\n* TBI 200 cGy Day -1\n* Equine ATG 30mg/Kg Days -6 to -4\n\nImmune suppression begin Day -3: cyclosporine and mycophenolate mofetil","id":"BG001","title":"Cyclophosphamide/Fludarabine/TBI/ATG"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"24","upperLimit":"67","value":"52.5"},{"groupId":"BG001","lowerLimit":"37","upperLimit":"68","value":"55.1"},{"groupId":"BG002","lowerLimit":"24","upperLimit":"68","value":"53.6"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"5"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"8"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"11"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"13"}]}],"title":"United States"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"9"}],"title":"AML (Acute Myeloid Leukemia)"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"CML (Chronic Myeloid Leukemia)"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"NHL (Non-Hodgkin's Lymphoma)"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}],"title":"MDS (Myelodysplastic Syndromes)"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Disease Diagnosis","unitOfMeasure":"Participants"}]}